Sulindac (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sulindac" in Italian language version.

refsWebsite

Global rank Italian rank

42nih.gov

4^th place

9^th place

18doi.org

2^nd place

7^th place

17oadoi.org

799^th place

22^nd place

8archive.org

6^th place

8^th place

archive.org

DC. Brater, S. Anderson; B. Baird; WB. Campbell, Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men., in Kidney Int, vol. 27, n. 1, Jan 1985, pp. 66-73, PMID 3884880.
DE. Duggan, LE. Hare; CA. Ditzler; BW. Lei; KC. Kwan, The disposition of sulindac., in Clin Pharmacol Ther, vol. 21, n. 3, Mar 1977, pp. 326-35, PMID 300048.
DS. Sitar, JA. Owen; B. MacDougall; T. Hunter; PA. Mitenko, Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac., in Clin Pharmacol Ther, vol. 38, n. 2, Aug 1985, pp. 228-34, PMID 4017423.
F. Bachmann, W. Hartl, [MK-231 (Sulindac) in the treatment of rheumatoid arthritis (author's transl)]., in Dtsch Med Wochenschr, vol. 102, n. 48, Dec 1977, pp. 1772-5, DOI:10.1055/s-0028-1105577, PMID 336322.
M. Atkinson, G. Germain; P. Lee, The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. A Canadian Multicentre Study., in J Rheumatol, vol. 15, n. 6, Jun 1988, pp. 1001-4, PMID 3047380.
A. Calin, M. Britton, Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin., in JAMA, vol. 242, n. 17, Oct 1979, pp. 1885-6, PMID 480622.
RW. Sloan, Hyperuricemia and gout., in J Fam Pract, vol. 14, n. 5, maggio 1982, pp. 923-6, 930-1, 934, PMID 7042900.
MY. Dawood, Nonsteroidal antiinflammatory drugs and reproduction., in Am J Obstet Gynecol, vol. 169, n. 5, Nov 1993, pp. 1255-65, PMID 8238194.

doi.org

dx.doi.org

F. Bachmann, W. Hartl, [MK-231 (Sulindac) in the treatment of rheumatoid arthritis (author's transl)]., in Dtsch Med Wochenschr, vol. 102, n. 48, Dec 1977, pp. 1772-5, DOI:10.1055/s-0028-1105577, PMID 336322.
DK. Li, L. Liu; R. Odouli, Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study., in BMJ, vol. 327, n. 7411, Aug 2003, p. 368, DOI:10.1136/bmj.327.7411.368, PMID 12919986.
CP. Torfs, EA. Katz; TF. Bateson; PK. Lam; CJ. Curry, Maternal medications and environmental exposures as risk factors for gastroschisis., in Teratology, vol. 54, n. 2, Aug 1996, pp. 84-92, DOI:10.1002/(SICI)1096-9926(199606)54:284::AID-TERA43.0.CO;2-4, PMID 8948544.
T. Mac Bird, JM. Robbins; C. Druschel; MA. Cleves; S. Yang; CA. Hobbs, Demographic and environmental risk factors for gastroschisis and omphalocele in the National Birth Defects Prevention Study., in J Pediatr Surg, vol. 44, n. 8, Aug 2009, pp. 1546-51, DOI:10.1016/j.jpedsurg.2008.10.109, PMID 19635303.
P. Frolov, J. Alali; MD. Klein, Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature., in Pediatr Surg Int, vol. 26, n. 12, Dec 2010, pp. 1135-48, DOI:10.1007/s00383-010-2701-7, PMID 20809116.
N. Giladi, D. Kazanov; B. Shpitz; I. Aroch; S. Kraus; N. Arber, Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer., in Expert Opin Investig Drugs, 19 Suppl 1, Apr 2010, pp. S117-24, DOI:10.1517/13543781003718841, PMID 20374023.
SD. Steinbrink, C. Pergola; U. Bühring; S. George; J. Metzner; AS. Fischer; AK. Häfner; JM. Wisniewska; G. Geisslinger; O. Werz; D. Steinhilber, Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations., in Cell Mol Life Sci, vol. 67, n. 5, Mar 2010, pp. 797-806, DOI:10.1007/s00018-009-0206-0, PMID 20091083.
NG. Nikitakis, MA. Scheper; VS. Papanikolaou; JJ. Sauk, The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac., in Oral Surg Oral Med Oral Pathol Oral Radiol Endod, vol. 107, n. 6, Jun 2009, pp. 826-36, DOI:10.1016/j.tripleo.2008.12.054, PMID 19272804.
FE. Rijcken, H. Hollema; AG. van der Zee; T. van der Sluis; W. Boersma-van Ek; JH. Kleibeuker, Sulindac treatment in hereditary non-polyposis colorectal cancer., in Eur J Cancer, vol. 43, n. 8, maggio 2007, pp. 1251-6, DOI:10.1016/j.ejca.2007.03.001, PMID 17434727.
JA. Zell, D. Pelot; WP. Chen; CE. McLaren; EW. Gerner; FL. Meyskens, Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas., in Cancer Prev Res (Phila), vol. 2, n. 3, Mar 2009, pp. 209-12, DOI:10.1158/1940-6207.CAPR-08-0203, PMID 19258540.
A. Kambe, H. Yoshioka; H. Kamitani; T. Watanabe; SJ. Baek; TE. Eling, The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells., in Cancer Prev Res (Phila), vol. 2, n. 12, Dec 2009, pp. 1088-99, DOI:10.1158/1940-6207.CAPR-09-0140, PMID 19934343.
T. Hayashi, H. Ishiwatari; H. Ihara; Y. Kawano; K. Takada; K. Miyanishi; M. Kobune; R. Takimoto; T. Sonoda; T. Takayama; J. Kato, Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms., in J Gastroenterol, vol. 44, n. 9, 2009, pp. 964-75, DOI:10.1007/s00535-009-0089-8, PMID 19536452.
MR. Pan, HC. Chang; WC. Hung, Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases., in Cell Signal, vol. 20, n. 6, Jun 2008, pp. 1134-41, DOI:10.1016/j.cellsig.2008.02.004, PMID 18374541.
Z. Song, C. Tong; J. Liang; A. Dockendorff; C. Huang; LH. Augenlicht; W. Yang, JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo., in Eur J Pharmacol, vol. 560, n. 2-3, Apr 2007, pp. 95-100, DOI:10.1016/j.ejphar.2007.01.020, PMID 17292881.
HN. Tinsley, BD. Gary; AB. Keeton; W. Zhang; AH. Abadi; RC. Reynolds; GA. Piazza, Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G., in Mol Cancer Ther, vol. 8, n. 12, Dec 2009, pp. 3331-40, DOI:10.1158/1535-7163.MCT-09-0758, PMID 19996273.
H. Zhou, W. Liu; Y. Su; Z. Wei; J. Liu; SK. Kolluri; H. Wu; Y. Cao; J. Chen; Y. Wu; T. Yan, NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling., in Cancer Cell, vol. 17, n. 6, Jun 2010, pp. 560-73, DOI:10.1016/j.ccr.2010.04.023, PMID 20541701.
A. Han, Z. Song; C. Tong; D. Hu; X. Bi; LH. Augenlicht; W. Yang, Sulindac suppresses beta-catenin expression in human cancer cells., in Eur J Pharmacol, vol. 583, n. 1, Mar 2008, pp. 26-31, DOI:10.1016/j.ejphar.2007.12.034, PMID 18291362.
DP. Kunte, RK. Wali; JL. Koetsier; HK. Roy, Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase., in Mol Cancer Ther, vol. 7, n. 7, Jul 2008, pp. 1797-806, DOI:10.1158/1535-7163.MCT-08-0022, PMID 18644992.

nih.gov

ncbi.nlm.nih.gov

DC. Brater, S. Anderson; B. Baird; WB. Campbell, Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men., in Kidney Int, vol. 27, n. 1, Jan 1985, pp. 66-73, PMID 3884880.
NM. Davies, MS. Watson, Clinical pharmacokinetics of sulindac. A dynamic old drug., in Clin Pharmacokinet, vol. 32, n. 6, Jun 1997, pp. 437-59, PMID 9195115.
N. Bayley, RW. Warne; RF. Moulds; RW. Bury, A kinetic study of sulindac in the elderly., in Aust N Z J Med, vol. 17, n. 1, Feb 1987, pp. 39-42, PMID 3476045.
DE. Duggan, LE. Hare; CA. Ditzler; BW. Lei; KC. Kwan, The disposition of sulindac., in Clin Pharmacol Ther, vol. 21, n. 3, Mar 1977, pp. 326-35, PMID 300048.
DS. Sitar, JA. Owen; B. MacDougall; T. Hunter; PA. Mitenko, Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac., in Clin Pharmacol Ther, vol. 38, n. 2, Aug 1985, pp. 228-34, PMID 4017423.
B. Delcambre, [Cooperative clinical study of Sulindac in arthrosis (hip joint and knee) in general medicine]., in Lille Med, vol. 22, 4 Suppl 1, Apr 1977, pp. 266-8, PMID 327175.
B. Brackertz, M. Busson, Comparative study of sulindac (Clinoril) and ibuprofen (Brufen) in osteoarthrosis., in Br J Clin Pract, vol. 32, n. 3, Mar 1978, pp. 77-80, PMID 352382.
F. Rainer, A. Ulreich; G. Klein, [A clinical trial of sulindac in osteoarthrosis]., in Z Rheumatol, vol. 39, n. 11-12, pp. 412-6, PMID 7025507.
F. Bachmann, W. Hartl, [MK-231 (Sulindac) in the treatment of rheumatoid arthritis (author's transl)]., in Dtsch Med Wochenschr, vol. 102, n. 48, Dec 1977, pp. 1772-5, DOI:10.1055/s-0028-1105577, PMID 336322.
HC. Burry, L. Witherington, A comparison of sulindac with ibuprofen in the management of rheumatoid arthritis., in N Z Med J, vol. 89, n. 634, Apr 1979, pp. 298-300, PMID 377154.
EC. Huskisson, [Experience with sulindac in rheumatoid arthritis and osteoarthritis]., in Reumatizam, vol. 27, n. 2, 1980, pp. 35-7, PMID 6996064.
K. Shichikawa, T. Saito; I. Nagaya; N. Ogawa, [Long-term multicenter, open label comparative study of sulindac and indomethacin in rheumatoid arthritis (author's transl)]., in Ryumachi, vol. 22, n. 2, Apr 1982, pp. 168-84, PMID 7051361.
M. Atkinson, G. Germain; P. Lee, The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. A Canadian Multicentre Study., in J Rheumatol, vol. 15, n. 6, Jun 1988, pp. 1001-4, PMID 3047380.
A. Calin, M. Britton, Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin., in JAMA, vol. 242, n. 17, Oct 1979, pp. 1885-6, PMID 480622.
T. Gibson, R. Laurent, Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study., in Rheumatol Rehabil, vol. 19, n. 3, Aug 1980, pp. 189-92, PMID 7414189.
AM. Nahir, Y. Scharf, A comparative study of diclofenac and sulindac in ankylosing spondylitis., in Rheumatol Rehabil, vol. 19, n. 3, Aug 1980, pp. 189-98, PMID 6997973.
W. Siegmeth, G. Hartmann; W. Sieberer, [Sulindac in the treatment of soft tissue rheumatism (periarthropathy of the hip and shoulder (author's transl)]., in Wien Med Wochenschr, vol. 130, n. 13-14, Jul 1980, pp. 492-5, PMID 7424040.
GN. Karachalios, G. Donas, Sulindac in the treatment of acute gout arthritis., in Int J Tissue React, vol. 4, n. 4, 1982, pp. 297-9, PMID 7169301.
RW. Sloan, Hyperuricemia and gout., in J Fam Pract, vol. 14, n. 5, maggio 1982, pp. 923-6, 930-1, 934, PMID 7042900.
GA. Oyemade, BO. Onadeko, A controlled clinical study comparing sulindac with ibuprofen and aspirin in the treatment of musculo-skeletal diseases., in J Int Med Res, vol. 7, n. 6, 1979, pp. 556-9, PMID 160348.
G. Letizia, F. Piccione, [Sulindac in orthopedics and traumatology]., in Clin Ter, vol. 90, n. 5, Sep 1979, pp. 481-7, PMID 550963.
GL. Nielsen, HT. Sørensen; H. Larsen; L. Pedersen, Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study., in BMJ, vol. 322, n. 7281, Feb 2001, pp. 266-70, PMID 11157526.
DK. Li, L. Liu; R. Odouli, Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study., in BMJ, vol. 327, n. 7411, Aug 2003, p. 368, DOI:10.1136/bmj.327.7411.368, PMID 12919986.
CP. Torfs, EA. Katz; TF. Bateson; PK. Lam; CJ. Curry, Maternal medications and environmental exposures as risk factors for gastroschisis., in Teratology, vol. 54, n. 2, Aug 1996, pp. 84-92, DOI:10.1002/(SICI)1096-9926(199606)54:284::AID-TERA43.0.CO;2-4, PMID 8948544.
T. Mac Bird, JM. Robbins; C. Druschel; MA. Cleves; S. Yang; CA. Hobbs, Demographic and environmental risk factors for gastroschisis and omphalocele in the National Birth Defects Prevention Study., in J Pediatr Surg, vol. 44, n. 8, Aug 2009, pp. 1546-51, DOI:10.1016/j.jpedsurg.2008.10.109, PMID 19635303.
P. Frolov, J. Alali; MD. Klein, Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature., in Pediatr Surg Int, vol. 26, n. 12, Dec 2010, pp. 1135-48, DOI:10.1007/s00383-010-2701-7, PMID 20809116.
P. Silvani, A. Camporesi, Drug-induced pulmonary hypertension in newborns: a review., in Curr Vasc Pharmacol, vol. 5, n. 2, Apr 2007, pp. 129-33, PMID 17430217.
MY. Dawood, Nonsteroidal antiinflammatory drugs and reproduction., in Am J Obstet Gynecol, vol. 169, n. 5, Nov 1993, pp. 1255-65, PMID 8238194.
N. Giladi, D. Kazanov; B. Shpitz; I. Aroch; S. Kraus; N. Arber, Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer., in Expert Opin Investig Drugs, 19 Suppl 1, Apr 2010, pp. S117-24, DOI:10.1517/13543781003718841, PMID 20374023.
SD. Steinbrink, C. Pergola; U. Bühring; S. George; J. Metzner; AS. Fischer; AK. Häfner; JM. Wisniewska; G. Geisslinger; O. Werz; D. Steinhilber, Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations., in Cell Mol Life Sci, vol. 67, n. 5, Mar 2010, pp. 797-806, DOI:10.1007/s00018-009-0206-0, PMID 20091083.
A. Sauter, H. Soulsby; K. Hormann; R. Naim, Sulindac sulfone induces a decrease of beta-catenin in HNSCC., in Anticancer Res, vol. 30, n. 2, Feb 2010, pp. 339-43, PMID 20332437.
NG. Nikitakis, MA. Scheper; VS. Papanikolaou; JJ. Sauk, The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac., in Oral Surg Oral Med Oral Pathol Oral Radiol Endod, vol. 107, n. 6, Jun 2009, pp. 826-36, DOI:10.1016/j.tripleo.2008.12.054, PMID 19272804.
FE. Rijcken, H. Hollema; AG. van der Zee; T. van der Sluis; W. Boersma-van Ek; JH. Kleibeuker, Sulindac treatment in hereditary non-polyposis colorectal cancer., in Eur J Cancer, vol. 43, n. 8, maggio 2007, pp. 1251-6, DOI:10.1016/j.ejca.2007.03.001, PMID 17434727.
JA. Zell, D. Pelot; WP. Chen; CE. McLaren; EW. Gerner; FL. Meyskens, Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas., in Cancer Prev Res (Phila), vol. 2, n. 3, Mar 2009, pp. 209-12, DOI:10.1158/1940-6207.CAPR-08-0203, PMID 19258540.
A. Kambe, H. Yoshioka; H. Kamitani; T. Watanabe; SJ. Baek; TE. Eling, The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells., in Cancer Prev Res (Phila), vol. 2, n. 12, Dec 2009, pp. 1088-99, DOI:10.1158/1940-6207.CAPR-09-0140, PMID 19934343.
T. Hayashi, H. Ishiwatari; H. Ihara; Y. Kawano; K. Takada; K. Miyanishi; M. Kobune; R. Takimoto; T. Sonoda; T. Takayama; J. Kato, Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms., in J Gastroenterol, vol. 44, n. 9, 2009, pp. 964-75, DOI:10.1007/s00535-009-0089-8, PMID 19536452.
MR. Pan, HC. Chang; WC. Hung, Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases., in Cell Signal, vol. 20, n. 6, Jun 2008, pp. 1134-41, DOI:10.1016/j.cellsig.2008.02.004, PMID 18374541.
Z. Song, C. Tong; J. Liang; A. Dockendorff; C. Huang; LH. Augenlicht; W. Yang, JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo., in Eur J Pharmacol, vol. 560, n. 2-3, Apr 2007, pp. 95-100, DOI:10.1016/j.ejphar.2007.01.020, PMID 17292881.
HN. Tinsley, BD. Gary; AB. Keeton; W. Zhang; AH. Abadi; RC. Reynolds; GA. Piazza, Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G., in Mol Cancer Ther, vol. 8, n. 12, Dec 2009, pp. 3331-40, DOI:10.1158/1535-7163.MCT-09-0758, PMID 19996273.
H. Zhou, W. Liu; Y. Su; Z. Wei; J. Liu; SK. Kolluri; H. Wu; Y. Cao; J. Chen; Y. Wu; T. Yan, NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling., in Cancer Cell, vol. 17, n. 6, Jun 2010, pp. 560-73, DOI:10.1016/j.ccr.2010.04.023, PMID 20541701.
A. Han, Z. Song; C. Tong; D. Hu; X. Bi; LH. Augenlicht; W. Yang, Sulindac suppresses beta-catenin expression in human cancer cells., in Eur J Pharmacol, vol. 583, n. 1, Mar 2008, pp. 26-31, DOI:10.1016/j.ejphar.2007.12.034, PMID 18291362.
DP. Kunte, RK. Wali; JL. Koetsier; HK. Roy, Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase., in Mol Cancer Ther, vol. 7, n. 7, Jul 2008, pp. 1797-806, DOI:10.1158/1535-7163.MCT-08-0022, PMID 18644992.

oadoi.org

DK. Li, L. Liu; R. Odouli, Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study., in BMJ, vol. 327, n. 7411, Aug 2003, p. 368, DOI:10.1136/bmj.327.7411.368, PMID 12919986.
CP. Torfs, EA. Katz; TF. Bateson; PK. Lam; CJ. Curry, Maternal medications and environmental exposures as risk factors for gastroschisis., in Teratology, vol. 54, n. 2, Aug 1996, pp. 84-92, DOI:10.1002/(SICI)1096-9926(199606)54:284::AID-TERA43.0.CO;2-4, PMID 8948544.
T. Mac Bird, JM. Robbins; C. Druschel; MA. Cleves; S. Yang; CA. Hobbs, Demographic and environmental risk factors for gastroschisis and omphalocele in the National Birth Defects Prevention Study., in J Pediatr Surg, vol. 44, n. 8, Aug 2009, pp. 1546-51, DOI:10.1016/j.jpedsurg.2008.10.109, PMID 19635303.
P. Frolov, J. Alali; MD. Klein, Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature., in Pediatr Surg Int, vol. 26, n. 12, Dec 2010, pp. 1135-48, DOI:10.1007/s00383-010-2701-7, PMID 20809116.
N. Giladi, D. Kazanov; B. Shpitz; I. Aroch; S. Kraus; N. Arber, Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer., in Expert Opin Investig Drugs, 19 Suppl 1, Apr 2010, pp. S117-24, DOI:10.1517/13543781003718841, PMID 20374023.
SD. Steinbrink, C. Pergola; U. Bühring; S. George; J. Metzner; AS. Fischer; AK. Häfner; JM. Wisniewska; G. Geisslinger; O. Werz; D. Steinhilber, Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations., in Cell Mol Life Sci, vol. 67, n. 5, Mar 2010, pp. 797-806, DOI:10.1007/s00018-009-0206-0, PMID 20091083.
NG. Nikitakis, MA. Scheper; VS. Papanikolaou; JJ. Sauk, The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac., in Oral Surg Oral Med Oral Pathol Oral Radiol Endod, vol. 107, n. 6, Jun 2009, pp. 826-36, DOI:10.1016/j.tripleo.2008.12.054, PMID 19272804.
FE. Rijcken, H. Hollema; AG. van der Zee; T. van der Sluis; W. Boersma-van Ek; JH. Kleibeuker, Sulindac treatment in hereditary non-polyposis colorectal cancer., in Eur J Cancer, vol. 43, n. 8, maggio 2007, pp. 1251-6, DOI:10.1016/j.ejca.2007.03.001, PMID 17434727.
JA. Zell, D. Pelot; WP. Chen; CE. McLaren; EW. Gerner; FL. Meyskens, Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas., in Cancer Prev Res (Phila), vol. 2, n. 3, Mar 2009, pp. 209-12, DOI:10.1158/1940-6207.CAPR-08-0203, PMID 19258540.
A. Kambe, H. Yoshioka; H. Kamitani; T. Watanabe; SJ. Baek; TE. Eling, The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells., in Cancer Prev Res (Phila), vol. 2, n. 12, Dec 2009, pp. 1088-99, DOI:10.1158/1940-6207.CAPR-09-0140, PMID 19934343.
T. Hayashi, H. Ishiwatari; H. Ihara; Y. Kawano; K. Takada; K. Miyanishi; M. Kobune; R. Takimoto; T. Sonoda; T. Takayama; J. Kato, Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms., in J Gastroenterol, vol. 44, n. 9, 2009, pp. 964-75, DOI:10.1007/s00535-009-0089-8, PMID 19536452.
MR. Pan, HC. Chang; WC. Hung, Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases., in Cell Signal, vol. 20, n. 6, Jun 2008, pp. 1134-41, DOI:10.1016/j.cellsig.2008.02.004, PMID 18374541.
Z. Song, C. Tong; J. Liang; A. Dockendorff; C. Huang; LH. Augenlicht; W. Yang, JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo., in Eur J Pharmacol, vol. 560, n. 2-3, Apr 2007, pp. 95-100, DOI:10.1016/j.ejphar.2007.01.020, PMID 17292881.
HN. Tinsley, BD. Gary; AB. Keeton; W. Zhang; AH. Abadi; RC. Reynolds; GA. Piazza, Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G., in Mol Cancer Ther, vol. 8, n. 12, Dec 2009, pp. 3331-40, DOI:10.1158/1535-7163.MCT-09-0758, PMID 19996273.
H. Zhou, W. Liu; Y. Su; Z. Wei; J. Liu; SK. Kolluri; H. Wu; Y. Cao; J. Chen; Y. Wu; T. Yan, NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling., in Cancer Cell, vol. 17, n. 6, Jun 2010, pp. 560-73, DOI:10.1016/j.ccr.2010.04.023, PMID 20541701.
A. Han, Z. Song; C. Tong; D. Hu; X. Bi; LH. Augenlicht; W. Yang, Sulindac suppresses beta-catenin expression in human cancer cells., in Eur J Pharmacol, vol. 583, n. 1, Mar 2008, pp. 26-31, DOI:10.1016/j.ejphar.2007.12.034, PMID 18291362.
DP. Kunte, RK. Wali; JL. Koetsier; HK. Roy, Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase., in Mol Cancer Ther, vol. 7, n. 7, Jul 2008, pp. 1797-806, DOI:10.1158/1535-7163.MCT-08-0022, PMID 18644992.